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comes. It is a 60-item questionnaire that contains the SF-
36 plus Pain Symptom, Functional Limitations, Perceived
Family/Social Disability, Real Family/Social Disability
and Formal Work Disability scales. RESULTS: Five 
thousand two hundred thirty-ﬁve TOPS instruments were
completed in 3,637 PMC patients from 1997 to 2002.
4,511 are <65 years, 392 are 65–74, and 332 are 75+.
Psychometric performance, evaluated with Cronbach’s
alpha index of internal consistency reliability, of the SF-
36/TOPS scales in this elderly population was consist-
ent with published validation standards. SF-36 Physical
Component Summary (PCS), Mental Component
Summary (MCS) and the TOPS Total Pain Experience
scales (TPE, a composite of 7 TOPS scales), for chronic
pain patients <65, 65–74 and >75 are: PCS (29.6, 27.9,
26.4), MCS (39.7, 42.2, 42.9), and TPE (60, 58.8, 61.1).
The PCS and MCS were signiﬁcantly different (p < 0.05)
when patients <65 were compared with older patients.
Top 5 ICD9 diagnoses in each age group accounted for
52–60% of diagnoses reported, with myalgia and myosi-
tis (729.1) and lumbago (724.2) being ﬁrst and second
ranked in each age group. Neuralgia, neuritis and radi-
culitis incidence was in the top ﬁve reported ICD9 diag-
noses for both older age groups, while herpes zoster
complications was reported only in the 75+ age group.
Inﬂuence of gender and work disability were also ana-
lyzed and will be presented. CONCLUSIONS: Older
chronic pain patients have a higher PCS, lower MCS,
similar TPE, and different diagnoses, as compared with
younger patients.
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OBJECTIVES: Tolterodine-ER is a newly-released 
medication for Overactive Bladder/Urinary Incontinence
(OAB/UI). This retrospective study investigated the dif-
ference in direct health-care cost, hospital utilization, and
medication persistence between OAB/UI patients initiated
with tolterodine-ER or oxybutynin-ER. METHODS:
Newly started adult patients (age > = 18) on either
tolterodine-ER or oxybutynin-ER from October 2001 to
May 2002 with 1-year washout period, were included
and followed up until the end of study period or disen-
rollment. The log-transformed direct healthcare cost
(excluding OAB-related pharmacy cost per member per
month) was analyzed by ANCOVA. Control variables
include demographics, previous hospital utilizations,
medication pattern, prior OAB diagnosis and comorbidi-
ties. A Cox Proportional Hazard model was applied to
examine the effect of different initial treatments on per-
sistence described by time to switch and time to discon-
tinuation. Logistic regression was used to assess the risk
of hospitalization associated with the ﬁrst prescription.
RESULTS: Of 1811 patients, 1021 patients started 
with tolterodine-ER, and 790 with oxybutynin-ER. The
average follow-up period for both groups was ﬁve
months. No signiﬁcant difference was found in the 
converted adjusted costs PMPM between tolterodine-ER
group (US$602) and oxybutynin-ER group (US$648)
with P = 0.324. Two groups had similar physician
encounter frequency (one visit PMPM) and emergency
room visit rate (2%), but tolterodine-ER initiated patients
were less frequently hospitalized (9.11% vs. 13.16%, P =
0.006). A higher proportion of oxybutynin-ER initiated
patients discontinued (56.6% vs. 52.5 %, P = 0.08) and
switched (7.85% vs. 7.54%, P = 0.808). The type of
initial therapy did not signiﬁcantly affect time to discon-
tinuation or time to switch, but initiating tolterodine-ER
could reduce the probability of hospitalization by 32%
(OR: 0.677, P = 0.037). CONCLUSIONS: Initial drug
selection did not signiﬁcantly change direct healthcare
cost, medical utilization, and medication persistence in
OAB/UI patients. However, patients initiating with oxy-
butynin-ER were exposed to a higher risk of hospitaliza-
tion than those initiating with tolterodine-ER.
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OBJECTIVES: Kidney failure affects approximately
300,000 people within the United States who require dial-
ysis therapy. Health care for affected patients is mainly
provided through the Medicare program. The literature
has shown that kidney failure has a signiﬁcant emotional,
psychological and ﬁnancial impact on affected patients
and society. There could be several factors that determine
patient utilization costs. Our objective is to identify the
demographic, clinical, and treatment facility factors that
signiﬁcantly explain the costs associated with kidney
failure treatment. METHODS: The study sample con-
sisted of 47,285 Medicare eligible dialysis patients. Data
were extracted for a 1-year period (1999). Predictor vari-
ables included patient demographics, treatment facility,
and several other kidney related laboratory test values
(such as creatinine clearance rates, co-morbidities, BUN,
and hematocrit at baseline). Outcome variables included
the dialysis treatment costs for epoetin and iron injec-
